We are studying how Ravulizumab works in children with Primary Immunoglobulin A Nephropathy. This research may help us understand its effects and safety in younger patients.
Health conditions and diseases that the clinical trial is designed to study and treat.
Immunoglobulin A Nephropathy (IgAN) is a rare kidney disorder where the immune system produces an abnormal amount of IgA antibodies, leading to inflammation and damage in the kidneys. This can result in symptoms like blood in urine, swelling, and high blood pressure.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
